Ellen Werber Leschek1, Armando C Flor2, Joy C Bryant3, Janet V Jones4, Kevin M Barnes5, Gordon B Cutler6. 1. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD. Electronic address: LeschekE@extra.niddk.nih.gov. 2. MedImmune, Gaithersburg, MD. 3. National Human Genome Research Institute, National Institutes of Health, Bethesda, MD. 4. Bastrop, TX. 5. The Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD. 6. Deltaville, VA.
Abstract
OBJECTIVE: Antiandrogen, aromatase inhibitor, and gonadotropin-releasing hormone analog (GnRHa) treatment normalizes growth rate and bone maturation and increases predicted adult height (AH) in boys with familial male-limited precocious puberty (FMPP). To evaluate the effect of long-term antiandrogen, aromatase inhibitor, and GnRHa on AH, boys with FMPP who were treated were followed to AH. STUDY DESIGN: Twenty-eight boys with FMPP, referred to the National Institutes of Health, were started on antiandrogen and aromatase inhibitor at 4.9 ± 1.5 years of age; GnRHa was added at 6.9 ± 1.5 years of age. Treatment was discontinued at 12.2 ± 0.5 years of age (bone age, 14.4 ± 1.3). AH was assessed at 16.4 ± 1.3 years of age (bone age, 18.5 ± 0.6). RESULTS: AH (mean ± SD) for all treated subjects was 173.6 ± 6.8 cm (-0.4 ± 1.0 SD relative to adult US males). For 25 subjects with pretreatment predicted AH, AH significantly exceeded predicted AH at treatment onset (173.8 ± 6.9 vs 164.9 ± 10.7 cm; P < .001), but fell short of predicted AH at treatment discontinuation (177.3 ± 9.0 cm; P < .001). For 11 subjects with maternal or sporadic inheritance, the mean AH was 3.1 cm (0.4 SD score) below sex-adjusted midparental height (175.4 ± 5.8 vs 178.5 ± 3.1 cm [midparental height]; P = .10). For 16 subjects with affected and untreated fathers, AH was significantly greater than fathers' AH (172.8 ± 7.4 vs 168.8 ± 7.2 cm; P < .05). CONCLUSIONS: Long-term treatment with antiandrogen, aromatase inhibitor, and GnRHa in boys with FMPP results in AH modestly below sex-adjusted midparental height and within the range for adult males in the general population. Published by Elsevier Inc.
OBJECTIVE: Antiandrogen, aromatase inhibitor, and gonadotropin-releasing hormone analog (GnRHa) treatment normalizes growth rate and bone maturation and increases predicted adult height (AH) in boys with familial male-limited precocious puberty (FMPP). To evaluate the effect of long-term antiandrogen, aromatase inhibitor, and GnRHa on AH, boys with FMPP who were treated were followed to AH. STUDY DESIGN: Twenty-eight boys with FMPP, referred to the National Institutes of Health, were started on antiandrogen and aromatase inhibitor at 4.9 ± 1.5 years of age; GnRHa was added at 6.9 ± 1.5 years of age. Treatment was discontinued at 12.2 ± 0.5 years of age (bone age, 14.4 ± 1.3). AH was assessed at 16.4 ± 1.3 years of age (bone age, 18.5 ± 0.6). RESULTS: AH (mean ± SD) for all treated subjects was 173.6 ± 6.8 cm (-0.4 ± 1.0 SD relative to adult US males). For 25 subjects with pretreatment predicted AH, AH significantly exceeded predicted AH at treatment onset (173.8 ± 6.9 vs 164.9 ± 10.7 cm; P < .001), but fell short of predicted AH at treatment discontinuation (177.3 ± 9.0 cm; P < .001). For 11 subjects with maternal or sporadic inheritance, the mean AH was 3.1 cm (0.4 SD score) below sex-adjusted midparental height (175.4 ± 5.8 vs 178.5 ± 3.1 cm [midparental height]; P = .10). For 16 subjects with affected and untreated fathers, AH was significantly greater than fathers' AH (172.8 ± 7.4 vs 168.8 ± 7.2 cm; P < .05). CONCLUSIONS: Long-term treatment with antiandrogen, aromatase inhibitor, and GnRHa in boys with FMPP results in AH modestly below sex-adjusted midparental height and within the range for adult males in the general population. Published by Elsevier Inc.
Authors: L Laue; D Kenigsberg; O H Pescovitz; K D Hench; K M Barnes; D L Loriaux; G B Cutler Journal: N Engl J Med Date: 1989-02-23 Impact factor: 91.245
Authors: Leandro Soriano-Guillén; Najiba Lahlou; Geneviève Chauvet; Marc Roger; Jean Louis Chaussain; Jean Claude Carel Journal: J Clin Endocrinol Metab Date: 2004-11-02 Impact factor: 5.958
Authors: E P Smith; J Boyd; G R Frank; H Takahashi; R M Cohen; B Specker; T C Williams; D B Lubahn; K S Korach Journal: N Engl J Med Date: 1994-10-20 Impact factor: 91.245
Authors: Chelsi Flippo; Vipula Kolli; Melissa Andrew; Seth Berger; Tricia Bhatti; Alison M Boyce; Daniel Casella; Michael T Collins; Emmanuèle Délot; Joseph Devaney; Stephen M Hewitt; Thomas Kolon; Ashwini Mallappa; Perrin C White; Deborah P Merke; Andrew Dauber Journal: J Endocr Soc Date: 2022-08-12
Authors: Duaa Althumairy; Xiaoping Zhang; Nicholas Baez; George Barisas; Deborah A Roess; George R Bousfield; Debbie C Crans Journal: Diseases Date: 2020-09-15
Authors: E Kohva; T Varimo; H Huopio; S Tenhola; R Voutilainen; J Toppari; P J Miettinen; K Vaaralahti; J Viinamäki; J T Backman; M Hero; T Raivio Journal: Hum Reprod Date: 2020-02-29 Impact factor: 6.918